Diagnóstico sin biopsia de la amiloidosis cardíaca por transtiretina

Julian D Gillmore¹, Mathew S Maurer¹, Rodney H Falk¹+29

• ¹From National Amyloidosis Centre, Division of Medicine (J.D.G., A.D.W., C.C.Q., H.J.L., T.R., M.F., K.F., T.L., F.W.V., C.J.W., D.F.H., P.N.H.) and Barts Heart Centre, Institute of Cardiovascular Science (J.C.M.), University College London, UK; Clinical Cardiovascular Research Laboratory for the Elderly, Columbia University Medical Center, New York (M.S.M., S.B., A.C.); Department of Cardiology and Department of Radiology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA (R.H.F., S.D.); Amyloidosis Research and Treatment Center, Foundation Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, and Department of Molecular Medicine, University of Pavia, Italy (G.M., G.P., P.M.); Department of Cardiology, University Hospital Henri Mondor, Amyloidosis Mondor Network, Creteil, France (T.D.); Division of Hematology, Division of Cardiovascular Diseases, and Department of Radiology, Division of Nuclear Medicine, Department of Medicine, Mayo Clinic, Rochester, MN (A.D., M.G., G.B.J.); Amyloidosis Center, Boston University School of Medicine and Boston Medical Center, MA (J.L.B., F.L.R.); Departments of Nuclear Medicine and Molecular Imaging (A.W.J.M.G.) and Rheumatology and Clinical Immunology (B.P.H.), University of Groningen, University Medical Center Groningen, The Netherlands; Department of Nuclear Medicine, S. Orsola-Malpighi Hospital, and Cardiology Unit, Department of Experimental, Diagnostic and Specialty Medicine, Alma Mater-University of Bologna, Italy (P.L.G., C.R.); and Yale University School of Medicine, Section of Cardiovascular Medicine, New Haven, CT (E.J.M.).